Komori
Japan Lifeline (7575) · InitiativeAchieved

Share Repurchases as a Flexible Capital Policy

First written in FY2016. 7 of 11 entries say "Advanced", first in FY2020-Q2. Latest entry: FY2025.

11entries
10years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2016 – FY2017AdvancedFY2020-Q2 – FY20252016: 120162017: 120172018: 020182019: 120192020: 020202021: 020212022: 220222023: 320232024: 220242025: 12025
Same theme, other companies
Flexible shareholder returns and capital policy through Board authorityA theme 410 companies write about · 0 as a headwind · 411 as a tailwind
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 199 companies compared. The sentences above are computed from all 199.Comparing 200 of the theme's 411 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2025AchievedAnnual report

    「Treasury shares acquired during the fiscal year 5,000,100 ¥5,225,104,500」

    The acquisition of treasury shares pursuant to the resolution of 1 May 2024 was completed during the fiscal year, involving 5,000,100 shares at an acquisition cost of ¥5,225 million.
  2. FY2025-H1AdvancedAnnual report

    「The Company acquired 5,000,100 treasury shares through a public tender offer for treasury shares conducted pursuant to a resolution of the Board of Directors meeting held on 1 May 2024.」

    The Company acquired 5,000,100 treasury shares through a public tender offer pursuant to the Board of Directors resolution of May 2024.
  3. FY2024-Q3AdvancedAnnual report

    「Pursuant to a resolution of the Board of Directors meeting held on 10 May 2023, the Company acquired 2,567,600 treasury shares for an acquisition cost of ¥2,758 million during the cumulative third quarter of the fiscal year.」

    Under the resolution of 10 May 2023 to acquire treasury shares, the Company acquired 2,567,600 shares for an acquisition cost of ¥2,758 million during the cumulative third quarter.
  4. FY2024-Q2AdvancedAnnual report

    「Pursuant to a resolution of the Board of Directors meeting held on 10 May 2023, the Company acquired 1,846,500 treasury shares for an acquisition cost of ¥1,937 million during the cumulative second quarter of the fiscal year.」

    Under the resolution of 10 May 2023 to acquire treasury shares, the Company acquired 1,846,500 shares for an acquisition cost of ¥1,937 million during the cumulative second quarter.
  5. FY2024-Q1AdvancedAnnual report

    「Pursuant to a resolution of the Board of Directors meeting held on 10 May 2023, the Company acquired 656,300 treasury shares for an acquisition cost of ¥693 million during the cumulative first quarter of the fiscal year.」

    Under the resolution of 10 May 2023 to acquire treasury shares, the Company acquired 656,300 shares for an acquisition cost of ¥693 million during the first quarter.
  6. FY2023AdvancedAnnual report

    「Status of resolution by the Board of Directors (10 May 2023) (acquisition period: 11 May 2023 to 29 February 2024) 3,000,000 shares (maximum) ¥4,000,000,000 (maximum)」

    In conjunction with the new medium-term management plan, the Company resolved to acquire up to 3 million shares or ¥4 billion of treasury shares, and had acquired 297,700 shares by the filing date.
  7. FY2023-Q1AchievedAnnual report

    「The Company completed the planned acquisition of treasury shares under the resolution of the Board of Directors by 1 July 2022 and cancelled the acquired shares on 15 July 2022.」

    Regarding the treasury share acquisition based on the resolution of 25 February 2022, the Company completed the acquisition of the planned 2,500,000 shares by 1 July 2022.
  8. FY2022AdvancedAnnual report

    「Status of resolution by the Board of Directors (25 February 2022) (acquisition period: 28 February 2022 to 31 August 2022) 2,500,000 shares (maximum) 3,500,000,000 (maximum)」

    Based on the resolution of 25 February 2022, the Company decided to acquire up to 2.5 million treasury shares for up to ¥3.5 billion, and acquired 501,300 shares for ¥539 million during the fiscal year.
  9. FY2020-Q2AdvancedAnnual report

    「This was due to ¥456 million in expenditures for the acquisition of treasury shares and ¥2,330 million in dividend payments, compared with expenditures of ¥0 million and ¥2,311 million, respectively, in the same period of the previous year.」

    The Company recorded ¥456 million in expenditures for the acquisition of treasury shares during the cumulative period of the second quarter, and carried out a treasury share repurchase.
  10. FY2017RestatedAnnual report

    「Under Article 165, Paragraph 2 of the Companies Act, the Company provides in its Articles of Incorporation that it may acquire its own shares through market transactions and other methods pursuant to a resolution of the Board of Directors. This is intended to enable the flexible execution of capital policies.」

    The Company reaffirmed the framework in its Articles of Incorporation for using treasury share repurchases as a means of executing flexible capital policies. During the current fiscal year, the acquisition was limited to 52 odd-lot shares.
  11. FY2016First statedAnnual report

    「The treasury shares acquired were purchased through a tender offer based on a resolution of the Board of Directors dated 30 April 2015, as outlined below: 1,500,000 shares acquired; total acquisition cost of ¥1,950 million」

    The Company acquired 1.5 million treasury shares for ¥1.95 billion through a tender offer conducted from May to July 2015.
Moved together

"Expansion of Unique, High-Value-Added Proprietary Products" moved the same way as this thread, in the same document, in 9 of its 11 moves.

976665★123456
  1. ★This thread
  2. 1Expansion of Unique, High-Value-Added Proprietary Products9×
  3. 2Expansion of medical devices beyond the cardiovascular field and entry into the gastrointestinal field7×
  4. 3Absorbing Declines in Product Prices and Achieving Stable Growth6×
  5. 4Entry into the Cerebrovascular Market with Vascular Embolization Coils6×
  6. 5Increase in the Sales Mix of High-Margin Proprietary Products6×
  7. 6Introducing the latest medical devices from overseas manufacturers to Japan5×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
Japan Lifeline's next results are scheduled for 2026-10-30. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Share Repurchases as a Flexible Capital Policy | Japan Lifeline Co.,Ltd. (7575) | Komori